The pressing need for SARS-CoV-2 controls has led to a reassessment of strategies to
identify and develop natural product inhibitors of zoonotic, highly virulent, and
rapidly emerging viruses. This review article addresses how contemporary approaches
involving computational chemistry, natural product (NP) and protein databases, and mass
spectrometry (MS) derived target–ligand interaction analysis can be utilized to
expedite the interrogation of NP structures while minimizing the time and expense of
extraction, purification, and screening in BioSafety Laboratories (BSL)3 laboratories.
The unparalleled structural diversity and complexity of NPs is an extraordinary resource
for the discovery and development of broad-spectrum inhibitors of viral genera,
including
Betacoronavirus
, which contains MERS, SARS, SARS-CoV-2, and
the common cold. There are two key technological advances that have created unique
opportunities for the identification of NP prototypes with greater efficiency: (1) the
application of structural databases for NPs and target proteins and (2) the application
of modern MS techniques to assess protein–ligand interactions directly from NP
extracts. These approaches, developed over years, now allow for the identification and
isolation of unique antiviral ligands without the immediate need for BSL3 facilities.
Overall, the goal is to improve the success rate of NP-based screening by focusing
resources on source materials with a higher likelihood of success, while simultaneously
providing opportunities for the discovery of novel ligands to selectively target
proteins involved in viral infection.